Your path to business agility
Innovation is all about focusing and optimizing the product portfolio so you can get products to market at the right time and cost. Topics we’ll explore in the Product Innovation blog category range from ideation management to product launch and product end-of-life. Experts will provide recommendations to take your innovation strategy and delivery process to the next level. You’ll get tips for picking the right projects, prioritizing good projects, and aligning them with strategy. Take your innovation strategy to the next level with information on improving time to market to maximize resources, funding, and time. Get tips from other customers on how they improved transparency to pick the right projects and kill the bad projects early. You will also be able to access ground-breaking research and fresh insights on how capacity planning can accelerate business innovation while lowering risk.
In this four-part series, I’m discussing some planning challenges and offering best practices that can help companies improve efficiencies and gain strategic advantage. In my last blog post I discussed “Is the annual process disconnected from the realities of your business?” In Part 2, I will talk about how executives and leadership need to rethink...
It doesn’t matter how much you think you’ve prepared, how many run-throughs you’ve done, how many assurances you have from your project teams that all the data will be there, and be correct. Something will go wrong: a critical piece of data will be missing, the slides will be wrong, an unanswerable question will derail...
Carrie Nauyalis New product development (NPD) solution evangelist Carrie Nauyalis is extremely passionate about the ROI of product portfolio management. She likes to walk the walk and talk the talk when it comes to championing a single source of the truth for greater efficiency in bringing products to market. In fact, she is such an advocate...
Under pressure to reduce costs, justify headcount, and deliver more while providing business sponsors with the status of projects? Do you feel like annual planning is a one-time exercise and not a true reflection of strategic objectives? You’re not alone. Many organizations find that the annual process is disconnected from the realities of the business....
It’s every portfolio manager’s nightmare. The annual portfolio review is about to kick off. Hundreds of hours of preparation have gone into the main presentation’s PowerPoint deck, and hundreds more into each of the backup decks, readied in case management asks about the details of any of the projects under discussion. Information encompassing over a...
For many years technology has played a critical role in improving both the efficiency and accuracy of processes through automation. Now, as technological capabilities continue to evolve, it is becoming more pervasive in all industries. The result is “Digital Business” and its exponential increase in the pace of technology-enabled products and services that impact us...
Wikipedia defines The Internet of Things (IoT) as the network of physical objects or “things” with embedded electronics, software, sensors, and connectivity to enable it to achieve greater value and service by exchanging data with the manufacturer, operator and/or other connected devices. Here’s more about the Internet of Things and product strategy. When I think...
While I spoke at the EBCG Portfolio Management in Life Sciences Conference, people started talking. I don’t mean in whispers, or on their mobiles behind their hands. It started a quietly, as a susurration, and became louder, until I momentarily stopped speaking to ask myself “is anyone paying attention?” The thing is, they were paying...
It seems every industry struggles in one way or another when it comes to developing and designing innovative, new products with that competitive edge. The way a company approaches innovation will differ from another company. That’s why I like this webcast The Right Way to Run Innovation Management featuring two of the most experienced product development gurus...
The past several months have seen a flurry of dealmaking in pharma and biotech. Pfizer, having been rebuffed by AstraZeneca, bought a manufacturer of biosimilars, increasing speculation that the company is planning to split itself in two. Shire, similarly stung by its failed attempt to buy AbbVie, is buying NPS pharmaceuticals. A very public drama...
